The biochemistry of disease: Desperately seeking syzygy

Annual Review of Biochemistry

Volumn 78, Issue , 2009, Pages 55-63

  Kozarich, John W ^a  

^a ACTIVX BIOSCIENCES INC   (United States)

Author keywords

Antibacterials; Antivirals; Bacterial resistance; Bisphosphonates; Protein misfolding diseases; Serpins

Indexed keywords

ALENDRONIC ACID; AMPRENAVIR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DAPTOMYCIN; DARUNAVIR; ENFUVIRTIDE; ETIDRONIC ACID; GS 8374; LINEZOLID; OSELTAMIVIR; PREALBUMIN; PRION PROTEIN; RISEDRONIC ACID; SERINE PROTEINASE INHIBITOR; SIALIDASE INHIBITOR; TIGECYCLINE; TMC 126; UNCLASSIFIED DRUG; ZANAMIVIR;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; BRAIN SPONGIOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR BIOLOGY; NONHUMAN; OSTEOPOROSIS; PHYSICAL DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; DISEASE; DRUG DISCOVERY; DRUG THERAPY; HUMANS;

BACTERIA (MICROORGANISMS);

EID: 67650725825     PISSN: 00664154     EISSN: 00664154     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-120108-082254     Document Type: Review

References (60)

1. Metcalf WW, van der Donk WA. 2009. Biosynthesis of phosphonic and phosphinic acid natural products. Annu. Rev. Biochem. 78:65-94
2. Fleisch H. 1998. Bisphosphonates: mechanisms of action. Endocr. Rev. 19:80-100
3. Rodan GA. 1998. Mechanisms of action of bisphosphonates. Annu. Rev. Pharmacol. Toxicol. 38:375-88
4. Fleisch H, Russell RG, Francis MD. 1969. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-64
5. Francis MD, Russell RG, Fleisch H. 1969. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264-66
6. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. 1997. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12:1358-67
7. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. 2000. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373:231-41
8. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. 1999. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264:108-11
9. Colman PM. 2009. New antivirals and drug resistance. Annu. Rev. Biochem. 78:95-118
10. Fleming DM. 2003. Zanamivir in the treatment of influenza. Expert Opin. Pharmacother. 4:799-805
11. Cass LM, Efthymiopoulos C, Bye A. 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36(Suppl. 1):1-11
12. Doucette KE, Aoki FY. 2001. Oseltamivir: a clinical and pharmacological perspective. Expert Opin. Pharmacother. 2:1671-83
13. He G, Massarella J, Ward P. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-84
14. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, et al. 1998. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitorGS4071. Antimicrob. Agents Chemother. 42:647-53
15. Callebaut C, Stray K, Tsai L, Xu L, He GX, et al. 2007. GS-8374, a novel phosphonate HIV protease inhibitor with potent in vitro antiretroviral activity, low metabolic toxicity, and favorable resistance profile. Antivir. Res. 74:A27
16. Cihlar T, He GX, Liu X, Chen JM, Hatada M, et al. 2006. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. J. Mol. Biol. 363:635-47
17. Fletcher CV. 2003. Enfuvirtide, a new drug for HIV infection. Lancet 361:1577-78
18. Nikaido H. 2009. Multidrug resistance in bacteria. Annu. Rev. Biochem. 78:119-46
19. Summers WC. 2001. Bacteriophage therapy. Annu. Rev. Microbiol. 55:437-51
20. Sulakvelidze A, Morris JG Jr. 2001. Bacteriophages as therapeutic agents. Ann. Med. 33:507-9
21. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2:489-97
22. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:3251-55
23. Slee AM, Wuonola MA, McRipley RJ, Zajac I, Zawada MJ, et al. 1987. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob. Agents Chemother. 31:1791-97
24. Ford CW, Hamel JC, Stapert D, Moerman JK, Hutchinson DK, et al. 1997. Oxazolidinones: new antibacterial agents. Trends Microbiol. 5:196-200
25. Saager B, Rohde H, Timmerbeil BS, Franke G, Pothmann W, et al. 2008. Molecular characterisation of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using Pyrosequencing. Eur. J. Clin. Microbiol. Infect Dis. 27:873-78
26. Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52:1570-72
27. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-46
28. Jones RN, Ross JE, Castanheira M, Mendes RE. 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62:416-26
29. Tedesco KL, Rybak MJ. 2004. Daptomycin. Pharmacotherapy 24:41-57
30. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. 2008. Daptomycin: a review 4 years after first approval. Pharmacology 81:79-91
31. Tally FP, DeBruin MF. 2000. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:523-26
32. Montero CI, Stock F, Murray PR. 2008. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob. Agents Chemother. 52:1167-70
33. Camargo IL, Neoh HM, Cui L, Hiramatsu K. 2008. Serial daptomycin selection generates daptomycinnonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52:4289-99
34. Rose WE, Rybak MJ. 2006. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 26:1099-110
35. Chopra I. 2001. Glycylcyclines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. 1:464-69
36. Navon-Venezia S, Leavitt A, Carmeli Y. 2007. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59:772-74
37. Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T, et al. 2007. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316:1759-61
38. Belogurov GA, Vassylyeva MN, Sevostyanova A, Appleman JR, Xiang AX, et al. 2009. Transcription inactivation through local refolding of the RNA polymerase structure. Nature 457:332-35
39. Lee S, Tsai FT. 2005. Molecular chaperones in protein quality control. J. Biochem. Mol. Biol. 38:259-65
40. Gregersen N, Bross P, Vang S, Christensen JH. 2006. Protein misfolding and human disease. Annu. Rev. Genomics Hum. Genet. 7:103-24
41. Gooptu B, Lomas DA. 2009. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu. Rev. Biochem. 78:147-76
42. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. 2003. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60:1119-22
43. Lansbury PT Jr, Caughey B. 1995. The chemistry of scrapie infection: implications of the 'ice 9' metaphor. Chem. Biol. 2:1-5
44. Coyle JT. 1999. Ice-nine and human prion disease. Harv. Rev. Psychiatry 6:331-33
45. Lindquist S, Krobitsch S, Li L, Sondheimer N. 2001. Investigating protein conformation-based inheritance and disease in yeast. Philos. Trans. R. Soc. Lond. Ser. B 356:169-76
46. Caughey B, Baron GS, Chesebro B, Jeffery M. 2009. Getting a grip on prions: oligomers, amyloids and pathological membrane interactions. Annu. Rev. Biochem. 78:177-204
47. Millhauser GL. 2007. Copper and the prion protein: methods, structures, function, and disease. Annu. Rev. Phys. Chem. 58:299-320
48. Davies P, Brown DR. 2008. The chemistry of copper binding to PrP: Is there sufficient evidence to elucidate a role for copper in protein function? Biochem. J. 410:237-44
49. Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, et al. 2003. Copper chelation delays the onset of prion disease. J. Biol. Chem. 278:46199-202
50. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008. Adapting proteostasis for disease intervention. Science 319:916-19
51. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR 3rd, et al. 2008. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134:769-81
52. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. 2005. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38:911-21
53. Johnson SM, Connelly S, Wilson IA, Kelly JW. 2008. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J. Med. Chem. 51:260-70
54. Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, et al. 2008. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Investig. 118:2858-67
55. Sawkar AR, D'Haeze W, Kelly JW. 2006. Therapeutic strategies to ameliorate lysosomal storage disorders - a focus on Gaucher disease. Cell Mol. Life Sci. 63:1179-92
56. Tropak MB, Kornhaber GJ, Rigat BA, Maegawa GH, Buttner JD, et al. 2008. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. ChemBioChem 9:2650-62
57. Yu Z, Sawkar AR, Kelly JW. 2007. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J. 274:4944-50
58. Yu Z, Sawkar AR, Whalen LJ, Wong CH, Kelly JW. 2007. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J. Med. Chem. 50:94-100
59. Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, et al. 2007. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. USA 104:13192-97
60. Tropak MB, Blanchard JE, Withers SG, Brown ED, Mahuran D. 2007. High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem. Biol. 14:153-64